Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Navelbine (Drug); Capecitabine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Dana-Farber Cancer Institute Official(s) and/or principal investigator(s): Craig A. Bunnell, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute
Summary
The purpose of this study is to find the highest dose of capecitabine and oral navelbine
that can be given without causing severe side effects, and to determine the safety,
tolerability, and effects (good and bad) of capecitabine given with oral navelbine to
patients with advanced breast cancer.
Clinical Details
Official title: A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To define the maximally tolerated dose and evaluate the feasibility and toxicity of capecitabine and oral navelbine administered in combination.
Detailed description:
- Not every patient will be receiving the same dose of capecitabine and navelbine. A
small group will be enrolled onto the study and given certain doses of each drug. If
they tolerate them well (have few or easily manageable side effects), the next small
group of people enrolled will receive a higher dose of one of the drugs. This will
continue until we find the highest doses of the drugs that can be given without causing
serious or unmanageable side effects.
- Patients will be given oral navelbine on days 1 and 8 of each cycle, unless they are at
the highest dose. In which case, they will be given navelbine on days 1, 8 and 15.
Capecitabine will be given on days 1-14 of each cycle in two divided doses
approximately 12 hours apart.
- While patients are on the study they will have the following tests and procedures
performed: physical examination every 3 weeks; routine blood work every week; extensive
laboratory tests every 3 weeks; disease status will be checked every 6 weeks (2 cycles)
unless there are symptoms of disease progression.
- The weekly treatment will continue unless there is disease progression or unacceptable
side effects.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Histologically confirmed breast cancer with evidence of locally advanced or
metastatic disease
- Female patients age 18 or older
- No more than three prior chemotherapeutic regimens in the metastatic setting
- ANC > 1,500/mm3
- Platelet count > 100,000/mm3
- SGOT < 3 x ULN
- Bilirubin < 1. 5 x ULN
- Performance status of 0 or 1
- At least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery
or any anticancer investigational agent
- Able to swallow and retain oral medications
- Measurable disease
Exclusion Criteria:
- Prior vinca alkaloids
- Active gastrointestinal disease or disorder
- Pregnant or lactating
- Serious co-morbid medical or psychological condition
- Prior bone marrow or stem cell transplant
- Prior documented severe sensitivity to 5-FU
Locations and Contacts
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Starting date: March 2002
Last updated: February 5, 2013
|